UNITED THERAPEUTICS Corp - Common Stock (UTHR)

Historical Holders from Q1 2014 to Q4 2025

Type / Class: Equity / Common Stock
Symbol: UTHR on Nasdaq
Shares outstanding: 44,798,018
Price per share: $487.25
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares as of 30 Sep 2025: 40,875,734
Total reported value: $17,137,629,356
% of total 13F portfolios: 0.02%
Share change: -2,995,478
Value change: -$1,069,670,491
Avg buy value change: +0.01%
Avg sell value change: -0.01%
Number of holders: 694
Price from insider filings: $510.00

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of UNITED THERAPEUTICS Corp - Common Stock (UTHR) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
STATE STREET CORP	4.9%		$644,114,243		2,199,994		STATE STREET CORPORATION	31 Dec 2024
WELLINGTON MANAGEMENT GROUP LLP	4.5%	-17%	$593,294,076	-$128,083,930	2,026,416	-18%	Wellington Management Group LLP	31 Mar 2025

As of 30 Sep 2025, UNITED THERAPEUTICS Corp - Common Stock (UTHR) has 694 institutional shareholders filing 13F forms. They hold 40,875,734 shares. of 44,798,018 outstanding shares (91%) .

Top 25 institutional shareholders own 61% of the company.

Filer	Ownership	Nb Shares	Share Change %	Portfolio %	Holdings Value
BlackRock, Inc.	12%	5,352,996	+0.36%	0.04%	$2,244,029,549
VANGUARD GROUP INC	9.9%	4,418,610	-0.68%	0.03%	$1,852,325,498
RENAISSANCE TECHNOLOGIES LLC	4.9%	2,173,392	+2.6%	1.2%	$911,107,660
Avoro Capital Advisors LLC	4.5%	2,022,222	-15%	11%	$847,735,685
STATE STREET CORP	4.3%	1,922,609	-11%	0.03%	$805,976,919
WELLINGTON MANAGEMENT GROUP LLP	3.1%	1,398,781	-3.1%	0.1%	$586,382,984
GEODE CAPITAL MANAGEMENT, LLC	2.8%	1,249,660	+4.1%	0.03%	$522,908,608
AQR CAPITAL MANAGEMENT LLC	2.2%	986,478	-23%	0.27%	$413,541,523
Darwin Global Management, Ltd.	1.7%	748,550		8.8%	$317,617,251
LSV ASSET MANAGEMENT	1.5%	686,710	-21%	0.64%	$287,876,000
ASSETMARK, INC	1.4%	645,908	-9.8%	0.58%	$270,771,197
Invesco Ltd.	1.4%	637,223	-28%	0.04%	$267,130,253
CITIGROUP INC	1.2%	551,470	+1197%	0.16%	$231,181,739
DIMENSIONAL FUND ADVISORS LP	1.1%	512,816	-11%	0.05%	$214,994,809
JANUS HENDERSON GROUP PLC	1%	454,718	+62%	0.09%	$190,569,761
NORTHERN TRUST CORP	1%	447,018	-1.2%	0.02%	$187,394,415
MORGAN STANLEY	0.98%	438,803	+10%	0.01%	$183,951,225
DEERFIELD MANAGEMENT COMPANY, L.P.	0.95%	425,993	-21%	2.7%	$178,580,526
Bank of New York Mellon Corp	0.78%	351,455	-3%	0.03%	$147,333,387
Pacer Advisors, Inc.	0.76%	339,071	-33%	0.36%	$142,141,954
Swedbank AB	0.73%	329,118	-0.45%	0.14%	$137,969,558
Pictet Asset Management Holding SA	0.72%	321,495	+52%	0.13%	$134,870,472
FULLER & THALER ASSET MANAGEMENT, INC.	0.7%	315,305	-19%	0.45%	$132,178,929
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	0.7%	312,948	-6.8%	0.02%	$131,190,931
PRICE T ROWE ASSOCIATES INC /MD/	0.67%	300,931	+163%	0.01%	$126,154,000

Institutional Holders of UNITED THERAPEUTICS Corp - Common Stock (UTHR) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (% of par)	Investors
2025 Q4	104,726	$51,420,603	+$14,608,860			48,725.07%	21
2025 Q3	40,875,734	$17,137,629,356	-$1,069,670,491	$1,202,086,828	$571,770,399	41,921%	694
2025 Q2	43,924,520	$12,621,621,981	-$132,393,669	$91,280,178	$97,653,099	28,735%	663
2025 Q1	44,378,846	$13,672,069,958	+$61,283,278	$37,639,767	$38,071,345	30,827%	659
2024 Q4	43,923,038	$15,501,991,244	+$187,675,652	$36,653,162	$43,246,420	35,284%	663
2024 Q3	43,091,175	$15,440,281,003	-$895,689,707	$105,569,910	$69,555,735	35,835%	617
2024 Q2	45,794,901	$14,582,299,264	+$483,642,559	$130,446,225	$117,290,110	31,855%	559
2024 Q1	44,668,215	$10,266,093,815	+$36,774,240	$121,613,768	$112,769,548	22,972%	517
2023 Q4	652,092	$143,343,779	+$8,235,029			21,989%	7
2023 Q3	43,524,236	$9,831,091,482	-$173,654,775	$31,712,148	$20,734,866	22,587%	496
2023 Q2	44,074,379	$9,727,755,731	-$249,429,682	$15,671,522	$20,064,063	22,075%	459
2023 Q1	44,647,136	$9,996,476,877	-$12,830,574	$17,561,464	$22,396,000	22,396%	491
2022 Q4	44,273,280	$12,309,140,520	+$52,941,634	$25,333,999	$29,922,484	27,809%	498
2022 Q3	43,465,728	$9,100,764,342	+$90,799,372	$42,607,000	$87,915,000	20,938%	436
2022 Q2	43,276,212	$10,167,776,291	+$121,668,106	$24,256,750	$61,621,000	23,564%	452
2022 Q1	43,386,665	$7,782,894,667	+$130,817,775	$48,020,000	$66,067,000	17,940.99%	406
2021 Q4	42,624,899	$9,209,865,142	-$255,129,444	$18,753,000	$41,200,208	21,608.03%	402
2021 Q3	43,517,178	$8,034,813,542	+$130,663,883	$55,579,000	$40,647,000	18,458%	409
2021 Q2	43,004,578	$7,714,135,399	+$18,696,460	$22,232,000	$41,902,000	17,941%	392
2021 Q1	42,199,091	$7,067,167,772	+$72,145,525	$72,101,320	$74,795,150	16,727%	380
2020 Q4	42,985,011	$6,525,391,483	+$195,664,438	$13,715,000	$36,250,714	15,178.96%	343
2020 Q3	41,458,638	$4,187,802,157	-$27,033,050	$5,859,000	$11,414,000	10,100%	314
2020 Q2	42,022,264	$5,083,365,436	-$62,885,303	$14,610,000	$18,938,000	12,100%	334
2020 Q1	42,317,827	$4,013,539,579	+$196,965,676	$13,523,000	$23,139,000	9,482.57%	288
2019 Q4	41,135,969	$3,622,553,098	-$14,393,169	$20,231,000	$22,576,000	8,807.98%	306
2019 Q3	40,479,716	$3,228,589,335	-$39,981,091	$29,907,000	$32,557,000	7,975.02%	286
2019 Q2	40,943,391	$3,194,308,708	-$110,413,587	$33,136,000	$26,859,000	7,805.97%	305
2019 Q1	42,668,638	$4,998,201,432	-$6,687,143	$36,760,000	$30,480,000	11,737.01%	361
2018 Q4	42,772,375	$4,644,656,939	-$44,680,615	$8,069,000	$6,274,000	10,889.84%	347
2018 Q3	42,400,368	$5,409,715,993	+$116,850,466	$20,870,000	$26,534,000	12,787.94%	354
2018 Q2	42,138,678	$4,757,224,858	-$111,489,973	$22,595,000	$31,483,000	11,314.94%	360
2018 Q1	43,327,389	$4,853,795,543	+$10,748,046	$22,720,000	$18,853,000	11,235.89%	361
2017 Q4	43,129,774	$6,361,909,413	+$197,931	$22,947,000	$20,358,000	14,794.97%	391
2017 Q3	43,659,867	$5,124,723,578	-$332,051,305	$25,864,000	$62,167,000	11,719%	364
2017 Q2	46,264,852	$6,004,918,581	-$218,808,511	$85,909,000	$11,851,000	12,973.02%	367
2017 Q1	47,725,280	$6,461,585,910	+$610,808,906	$57,331,000	$60,622,000	13,538%	401
2016 Q4	46,844,613	$6,713,728,830	-$108,523,542	$26,530,000	$31,456,000	14,342.95%	393
2016 Q3	48,590,495	$5,734,932,105	-$90,470,103	$25,351,000	$23,522,000	11,808%	383
2016 Q2	49,313,016	$5,224,505,518	-$125,744,632	$26,238,000	$26,852,000	10,591.94%	372
2016 Q1	50,640,999	$5,643,804,733	-$78,575,975	$25,960,000	$32,419,000	11,142.89%	390
2015 Q4	49,748,458	$7,792,616,829	-$12,044,878	$22,611,000	$47,794,000	15,661.01%	372
2015 Q3	49,983,276	$6,560,104,627	-$69,193,348	$35,228,000	$20,840,000	13,123.99%	360
2015 Q2	50,377,944	$8,762,290,786	-$264,447,068	$33,184,000	$47,710,000	17,395%	378
2015 Q1	52,358,250	$9,021,227,777	+$258,694,966	$42,999,000	$63,153,000	17,243.48%	365
2014 Q4	50,481,729	$6,541,552,799	-$247,055,871	$34,435,000	$34,983,000	12,949%	328
2014 Q3	52,842,225	$6,798,751,692	+$110,623,345	$52,582,000	$76,536,000	12,865.03%	318
2014 Q2	52,197,884	$4,620,244,446	-$1,253,814,742	$28,070,000	$31,585,000	8,849%	303
2014 Q1	53,381,219	$5,019,682,084	-$140,614,405	$13,484,000	$7,155,000	9,402.97%	303